Tildrakizumab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Tildrakizumab is a high-affinity, humanized, IgG1 kappa antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3
• The Food and pharmaceutical Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018
• The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter 7
• A study was performed on the pharmacokinetics of this pharmaceutical on various ethnicities
• The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5.